Brief: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
07/11/2025 14:05
Nov 7 (Reuters) - Xilio Therapeutics Inc XLO.O: XILIO THERAPEUTICS ANNOUNCES LATE-BREAKING PHASE 2 DATA FOR VILASTOBART IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING Source text: ID:nGNX2c3qld Further company coverage: XLO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla